Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

72 results about "Gastrointestinal motility disorder" patented technology

Method and compositions for the treatment of gastrointestinal disorders

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Methods and compositions for the treatment of gastrointestinal disorders

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Method for treating congestive heart failure and other disorders

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.
Owner:OCERA THERAPEUTICS INC

Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.
Owner:OCERA THERAPEUTICS INC

Compositions And Methods For Transmucosal Delivery Of Domperidone

Compositions of domperidone formulated for transmucosal delivery are provided. Also provided are methods for the treatment of nausea, vomiting, and gastrointestinal motility disorders, and methods for the enhancement of breast milk production. The methods utilize domperidone compositions formulated for transmucosal administration, administered to patients in an amount effective to treat nausea, vomiting, or gastrointestinal motility disorders, or to enhance breast milk production.
Owner:ARONCHICK CRAIG A

Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders

ActiveUS20100093720A1BiocidePeptide/protein ingredientsGastrointestinal dysmotilityStress induced
The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
Owner:OCERA THERAPEUTICS INC

A digestive tract power detection system

InactiveCN102293635ADiagnostic recording/measuringSensorsDiseaseAnorectal pressure
A digestive tract power detection system relates to the field of digestive tract power detection, including an eight-lead gastrointestinal electrogram detection system, a pressure detection system and a software control system. The pressure detection system includes an esophageal pressure detection system and anorectal pressure detection system. Through the software control system, the instrument conducts two-way data transmission between the eight-lead gastrointestinal electrogram detection system, esophageal pressure detection system and anorectal pressure detection system, and realizes the collection of esophageal dynamic detection, anorectal dynamic detection and eight-lead gastrointestinal electrogram detection Digestive tract motility detection system with three functions in one. The best effect is that the digestive tract dynamic detection system embodies the highly integrated circuit technology of the gastrointestinal electrogram detection system and pressure detection system, and integrates signal processing circuits such as signal amplification, active filtering, feedback and control, power amplification and A / A series of circuits such as D conversion are integrated on a computer-specific detection card; and many information processing and automatic control technologies such as electrophysiological signal processing technology, pressure source constant pressure control technology of pressure detection system, automatic control software and data analysis are adopted. Processing technology and database management technology bring great convenience to the diagnosis and research of digestive tract motility diseases, and more accurate and comprehensive diagnosis and research of digestive tract motility diseases.
Owner:HEFEI KAILI PHOTOELECTRIC TECH

Treatments for Gastrointestinal Disorders

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof

ActiveCN102068535APromote gastric motilityVomiting worksDigestive systemPlant ingredientsMacroporous resinImpurity
The invention relates to an immature bitter orange or bitter orange total flavonoids extract, which is prepared by the following steps of: cutting bitter orange or bitter orange into slices or crushing bitter orange or bitter orange, adding 30 to 90 percent ethanol of 5 to 16 times volume for reflux and extraction for 1 to 3 times and 1 to 3 hours every time, and filtering; and combining the filtrate, reclaiming the ethanol from the filtrate, filling the aqueous solution into the treated non-polar macroporous resin, diluting in turn by using water and less than 20 percent ethanol to remove impurities, diluting by using 25 to 90 percent ethanol and 0.5 to 2 percent sodium hydroxide, collecting ethanol eluent, concentrating the ethanol eluent under reduced pressure to obtain fluid extract with relative density of about 1.20 to 1.40 (50 to 70 DEG C), drying the fluid extract under the reduced pressure at the temperature of between 60 and 80 DEG C, and crushing to obtain the immature bitter orange or bitter orange total flavonoids extract. The extract can be used for preparing medicaments for gastrointestinal motility disorder type functional indigestion, epigastric pain, abdominal distention, asitia, belching, nausea, sickness and chemotherapy or sickness caused by other reasons.
Owner:JIANGZI QINGFENG PHARMACEUTICALS INC

Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, purity, ease of preparation and / or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
Owner:MERCK SHARP & DOHME LLC

Application of patchoulicalcohol in preparation of medicines for treating gastric motility disorders

The invention discloses a new use of patchoulicalcohol, that is, an application of patchoulicalcohol in the preparation of medicines or health products for preventing and treating gastric motility disorders. Researches in the invention show that patchoulicalcohol can inhibit the contraction of gastrointestinal smooth muscles, can inhibit the relaxation of the gastrointestinal smooth muscle, and can reduce the overall tension level of the gastrointestinal smooth muscles; and patchoulicalcohol can selectively block the nerve conduction of the smooth muscles, has a significant curative effect on gastrointestinal motility disorders, and is dose dependent. The invention provides a new medicine choice for the gastrointestinal motility disorders, and also provides a new research approach to explore gastrointestinal nerve conduction antagonists. Patchoulicalcohol has no dose toxicity or genetic toxicity and is highly safe, so the daily application dosage is not strictly restricted from a security point of view, the dosage can be adjusted according to practical conditions, so the wide application of patchoulicalcohol is guaranteed, and patchoulicalcohol has a very good popularization application prospect.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same

The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.
Owner:DONG A ST CO LTD

Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same

The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.
Owner:DONG A ST CO LTD

Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and / or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
Owner:DOLLE ROLAND E +5

Compositions useful for treating gastrointestinal motility disorders

InactiveUS20050059704A1Enhanced and synergistic therapeutic effectGood effectBiocideDigestive systemGastrointestinal motility disorderEsophageal motility
The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an H2 receptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HT3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HT3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.
Owner:EDUSA PHARMA

Ultrasound neuromodulation treatment of gastrointestinal motility disorders

Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound to treat gastrointestinal motility disorders. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, pulse pattern, and phase / intensity relationships to targeting and accomplishing up regulation and / or down regulation.
Owner:MISHELEVICH DAVID J

Compositions and methods for treating gastrointestinal motility dysfunction

Extended release oral dosage forms for the treatment of gastrointestinal motility disorders are described. Active agents which are small molecules, peptides, peptide analogs, and peptide mimetics are formulated for optimal release in the GI tract of subjects with GI motility dysfunction. Methods of treatment using the dosage forms are also described.
Owner:DEPOMED SYST INC

New effect and applications of trans-acomhole

The invention discloses a new effect and applications of trans-acomhole, relating to three new applications of the trans-acomhole in preparation of drugs or health care products for preventing and treating enterocoelia adhesion after an enterocoelia operation, abdominal distension as well as functional gastrointestinal disorder and poor digestion and malabsorption. By intervening the trans-acomhole through an animal model and a clinic test by the applicant, the trans-acomhole is proved to be capable of being used as the drugs or health care products for preventing and treating the enterocoelia adhesion after the enterocoelia operation, the abdominal distension as well as the functional gastrointestinal disorder and poor digestion and malabsorption. The drugs or health care products can be preparations for external application, oral preparations or intraperitoneal injection preparations.
Owner:周彦芳

Methods and Compositions for the Treatment of Gastrointestinal Disorders

The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Pharmaceutical composition and its preparation method and use

The invention provides a pharmaceutical composition and its preparation method and use. The pharmaceutical composition comprises, by weight, 1-15 parts of adenosine, 20-40 parts of adenine, 10-25 parts of uracil, 10-28 parts of serine, 1-10 parts of tryptophan, 20-35 parts of adenine, 8-25 parts of arginine, 10-26 parts of glutamic acid, 1-15 parts of alanine and 10-25 parts of dopamine. The pharmaceutical composition has substantial treatment effects on irritable bowel syndrome, ulcerative colitis, gastric ulcer, peptic ulcer, diabetic foot ulcer, gastrointestinal motility disorder, eczema, anal fissure, gastroesophageal reflux disease and fungal infection, has no toxic or side effect, has high safety and has a low recurrence rate.
Owner:SICHUAN GOODDOCTOR PANXI PHARMA

New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof

The invention belongs to the field of traditional Chinese medicinal preparations and in particular relates to a new pharmaceutical composition capable of promoting gastrointestinal motility and a preparation method thereof. The new pharmaceutical composition capable of promoting the gastrointestinal motility is prepared from the raw materials of fructus aurantii and rhizoma cyperi in ratio of parts by weight of 1:(1-10). The new pharmaceutical composition capable of promoting the gastrointestinal motility can be used for effectively preventing and treating gastrointestinal motility disorders and has an obvious promoting effect on the gastrointestinal motility.
Owner:辽宁华润本溪三药有限公司

Combination medicine based on active components in Fructus Aurantii, and use thereof

The invention relates to a combination medicine based on active components in Fructus Aurantii. The combination medicine comprises, by mass, 9-72% of naringin, 9-72% of neohesperidin, 1-15% of naringenin, 1-15% of hesperetin, and the balance of a medicinal filling auxiliary material. Dose-effect experiments of the main medicine effect components comprising naringin, neohesperidin, naringenin and hesperetin in the traditional Chinese medicine Fructus Aurantii are carried out to carry out composition optimization, and the combination medicine can condition the rising and falling motion of the spleen and the stomach to promote gastrointestinal motility in order to treat gastrointestinal motility disorder, so the combination medicine can be used to treat the gastrointestinal motility disorder disease, and has god exploitation prospect. Compared with present gastric motility promotion medicines, the combination medicine has the advantages of convenient sources of the raw materials, substantial curative effect and no toxic or side effects.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Muscarinic receptor antagonists

The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.
Owner:RANBAXY LAB LTD

Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders

ActiveUS9133235B2BiocidePeptide/protein ingredientsGastrointestinal dysmotilityPharmacometrics
The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
Owner:OCERA THERAPEUTICS INC

Composition containing herbal medicine extracts of pinellia and scutellaria for reducing side effects due to anticancer drugs

The present invention relates to a composition containing a Pinelliae Rhizoma and Scutellariae Radix extract as an active ingredient to reduce side effects caused by an anticancer drug, and more particularly, a composition for reducing side effects such as damage to the gastrointestinal tract and a gastrointestinal motility disorder by administering an anticancer drug. The composition of the present invention has an excellent effect of reducing side effects in administration of the anticancer drug through an antioxidative function, and synthesis, secretion and control of the functions of gastrin and serotonin producing gastrointestinal endocrine cells.
Owner:COMPREHENSIVE & INTEGRATIVE MEDICINE INST

Fructus aurantii quality marker and screening method and application thereof

The invention discloses a fructus aurantii quality marker and a screening method thereof. The method includes the steps that firstly, chemical phenotypes and difference components of Jiangxi genuine fructus aurantii and non-genuine fructus aurantii are compared, and finally, a chemical component group with the stomach invigorating effect in fructus aurantii is determined through pharmacological research on serum medicinal chemistry and in-vitro, in-vivo and virtual stomach invigorating activity screening. It is found that intragastric administration through the fructus aurantii extract can remarkably resist atropine-induced gastrointestinal motility disorder, the chemical component group capable of reflecting clinical medication effectiveness of fructus aurantii is finally determined through screening of the stomach invigorating activity of in-vitro chemical components, and the chemical component group can serve as a quality marker of fructus aurantii, and the quality control of the fructus aurantii based on the medicinal components is realized. According to the invention, the traditional Chinese medicine quality control problems that the quality of fructus aurantii medicinal materials is uneven, the clinical efficacy is unstable, the traditional fructus aurantii quality standard does not reflect the unrelated efficacy and the like are solved.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI

Salsola collina and curcuma aromatica composition, preparation method thereof and application of salsola collina and curcuma aromatica composition in preparation of medicines for promoting gastrointestinal motility

The invention relates to a natural medicine composition, a preparation method thereof and application of the natural medicine composition in preparation of medicines for promoting gastrointestinal motility. The natural medicine composition is prepared from salsola collina and curcuma aromatica decoction concentrated extract, salsola collina ethanol extract, curcuma aromatica ethanol extract and curcumine in a ratio of (5-8):(3-9):(3-8):(1-3). The composition has a remarkable motility promoting function on both normal animal stomach and intestines and motility inhibited animal stomach and intestines, can be used for preparing medicines for promoting gastrointestinal motility and treating gastrointestinal motility disorder with exact curative effect and no remarkable toxic or side effect, and has an excellent application prospect.
Owner:王宏波 +1

Medicine composition for treating gastrointestinal motility disorder

ActiveCN103285326AQuick responseStrengthen the effect of eliminating stagnation and stagnationDigestive systemPlant ingredientsGastrointestinal motility disorderTraditional medicine
The invention relates to a medicine composition for treating gastrointestinal motility disorder. The composition is characterized by comprising the following raw medicines in parts by weight: 10-20 parts of zedoary, 7-15 parts of fructus amomi, 7-15 parts of betel nut, 7-15 parts of costus root and 7-15 parts of spikenard. According to the technical scheme, zedoary, fructus amomi, betel nut, costus root and spikenard are composited on the basis of theory of traditional Chinese medicine and through the adjustment of the lifting motion of spleen and stomach and the synergistic effect on the aspects of promoting qi circulation, resolving dampness, eliminating accumulation, stopping pain and the like, the purposes of promoting gastrointestinal motility and treating gastrointestinal motility disorder are achieved.
Owner:苏州市中医医院 +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products